Lack of Either Estrogen or Progesterone Receptor Expression Is Associated with Poor Survival Outcome among Luminal A Breast Cancer Subtype

Park, Seho; Park, Byeong Woo; Kim, Tae Hyun; Jeon, Chang Wan; Han, Kang; Choi, Jung Eun; Hwang, Kihwan; Kim, In Cheol

doi:10.1245/s10434-012-2772-x

Cited by 32 publications

(35 citation statements)

References 38 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial search strategy identified 3900 articles, of which 51 full articles were deemed eligible for review. After application of inclusion and exclusion criteria, eight studies were selected for inclusion ( Fig . ).…”

Section: Resultsmentioning

confidence: 99%

“…Clinicopathological characteristics, including T category, HER2 status, grade, nodal positivity and Ki‐67 index results are summarized in Table . Six of the eight studies reported mean age for both groups; the mean age in the ER+PgR– and ER+PgR+ groups was 53·1 (range 46–58) and 49·6 (range 46–48) years respectively ( Table S1 , supporting information). Four studies reported on the menopausal status of patients at diagnosis; 3497 of 5363 (65·2 per cent) were premenopausal in the ER+PgR+ group compared with 282 of 776 (36·3 per cent) in the ER+PgR– group.…”

Section: Resultsmentioning

confidence: 99%

“…Treatment characteristics were available in five of the eight included studies ( Table ). In the ER+PgR– group, data with regard to patients who underwent mastectomy as surgical treatment were available from four studies. In these studies, 2468 of 6295 patients (39·2 per cent) underwent mastectomy in the ER+PgR+ group, compared with 449 of 900 (49·9 per cent) in the ER+PgR– group.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Boland

Ryan

Dunne

et al. 2020

Journal of British Surgery

View full text Add to dashboard Cite

Background: Assessment of the oestrogen receptor (ER) provides important prognostic information in breast cancer. The impact of progesterone receptor (PgR) status is less clear. Standardization of immunohistochemical analysis of these receptors has reduced interstudy heterogeneity. The aim of this meta-analysis was to evaluate the impact of PgR negativity on outcomes in ER-positive (ER+) breast cancer.Methods: This study was performed according to PRISMA and MOOSE guidelines. PubMed, Embase and the Cochrane Library were searched systematically to identify studies comparing disease-free survival as the primary outcome and overall survival as secondary outcome between PgR-positive (PgR+) and PgR-negative (PgR-) status in ER+ breast cancer. A meta-analysis of time-to-effect measures from included studies was undertaken.Results: Eight studies including 13 667 patients, 11 838 in the ER+PgR+ group and 1829 in the ER+PgR-group, met the inclusion criteria. Treatment characteristics did not differ significantly between the two groups. Patients in the ER+PgR-group had a higher risk of disease recurrence than those who had ER+PgR+ disease (hazard ratio (HR) 1⋅57, 95 per cent c.i. 1⋅38 to 1⋅79; P < 0⋅001). This hazard was increased in patients with human epidermal growth factor receptor 2-negative tumours (HR 1⋅62, 1⋅37 to 1⋅93; P < 0⋅001). A similar result was observed for overall survival (HR 1⋅69, 1⋅33 to 2⋅14; P < 0⋅001).Conclusion: PgR negativity is associated with significant reductions in disease-free and overall survival in ER+ breast cancer. Treatment and surveillance strategies in these patients should be tailored accordingly.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Boland

Ryan

Dunne

et al. 2020

Journal of British Surgery

View full text Add to dashboard Cite

show abstract

“…Consequently, it seems that molecular subtypes might be divided into additional subgroups with further data from transcriptomic analyses. For example, the lack of ESR1 or PGR receptors in luminal A subtype can define new subgroups with unique clinicopathologic characteristics [25]. Further molecular markers are capable to estimate prognosis in a subtype-independent manner using claudin expression [26].…”

Section: The Discovery Of Molecular Subtypesmentioning

confidence: 99%

Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis

Mihály

Győrffy

2013

Microarrays

View full text Add to dashboard Cite

Breast cancer research has paved the way of personalized oncology with the introduction of hormonal therapy and the measurement of estrogen receptor as the first widely accepted clinical biomarker. The expression of another receptor—HER2/ERBB2/neu—was initially a sign of worse prognosis, but targeted therapy has granted improved outcome for these patients so that today HER2 positive patients have better prognosis than HER2 negative patients. Later, the introduction of multigene assays provided the pathologists with an unbiased assessment of the tumors’ molecular fingerprint. The recent FDA approval of complete microarray pipelines has opened new possibilities for the objective classification of breast cancer samples. Here we review the applications of microarrays for determining ER and HER2 status, molecular subtypes as well as predicting prognosis and grade for breast cancer patients. An open question remains the role of single genes within such signatures. Openly available microarray datasets enable the execution of an independent cross-validation of new marker and signature candidates. In summary, we review the current state regarding clinical applications of microarrays in breast cancer molecular pathology.

show abstract

“…After binding to their respective intracellular receptors [Estrogen Receptor (ER) and Progesterone Receptor (PR)] both these hormones activate a set of signalling events that ultimately result in enhancing the cellular proliferation rate of normal breast epithelium 4 . ER−/PR− breast tumors are shown to have a poor prognosis compared to ER+/PR+ tumors 5 . Similarly, human epidermal growth factor (Her2neu) status is one of the other determinants of the rate of breast tumor proliferation, with Her2neu+ tumors representing a more aggressive form 6 .…”

Section: Introductionmentioning

confidence: 99%

Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA

Agarwal

Hariprasad

Rani

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Total choline (tCho) was documented as a biomarker for breast cancer diagnosis by in vivo MRS. To understand the molecular mechanisms behind elevated tCho in breast cancer, an association of tCho with β-catenin and cyclin D1 was evaluated. Hundred fractions from 20 malignant, 10 benign and 20 non-involved breast tissues were isolated. Cytosolic and nuclear expressions of β-catenin and cyclin D1 were estimated using ELISA. Higher tCho was seen in malignant compared to benign tissues. Malignant tissues showed higher cytosolic and nuclear β-catenin expressions than benign and non-involved tissues. Within malignant tissues, β-catenin and cyclin D1 expressions were higher in the nucleus than cytosol. Cyclin D1 expression was higher in the cytosolic fractions of benign and non-involved than malignant tissues. Furthermore, in malignant tissues, tCho showed a positive correlation with the cytosolic and nuclear expression of β-catenin and cyclin D1 and also a correlation between nuclear expressions of both these proteins was seen. Higher cytosolic β-catenin expression was seen in progesterone receptor negative than positive patients. Results provide an evidence of correlation between non-invasive biomarker, tCho and the Wnt/β-catenin pathway. The findings explain the molecular mechanism of tCho elevation which may facilitate exploration of additional therapeutic targets for breast cancer.

show abstract

Lack of Either Estrogen or Progesterone Receptor Expression Is Associated with Poor Survival Outcome among Luminal A Breast Cancer Subtype

Abstract: Current results suggest that the luminal A subtype is also heterogeneous and each subgroup has unique clinicopathologic characteristics. Lack of either ER or PR expression is associated with worse survival, especially among node-positive luminal A subtype.

Cited by 32 publications

References 38 publications

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer

Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis

Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA

Contact Info

Product

Resources

About